Cargando…

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure

BACKGROUND: Emerging data from pre-clinical and clinical studies suggest that HER-2/neu-specific T cell responses could induce HER-2/neu antigen loss in the tumor cells. These data suggest that patients with HER-2/neu negative breast cancer might have had HER-2/neu positive premalignant lesions in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kmieciak, Maciej, Payne, Kyle K, Idowu, Michael O, Grimes, Margaret M, Graham, Laura, Ascierto, Maria-Libera, Wang, Ena, Wang, Xiang-Yang, Bear, Harry D, Manjili, Masoud H
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076247/ https://www.ncbi.nlm.nih.gov/pubmed/21453513 http://dx.doi.org/10.1186/1479-5876-9-35

Ejemplares similares

IFN-γ Rα Is a Key Determinant of CD8+ T Cell-Mediated Tumor Elimination or Tumor Escape and Relapse in FVB Mouse
por: Kmieciak, Maciej, et al.
Publicado: (2013)

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
por: Gowda, Madhu, et al.
Publicado: (2011)

Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells
por: Payne, Kyle K, et al.
Publicado: (2013)

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function
por: Kmieciak, Maciej, et al.
Publicado: (2009)

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy
por: Aqbi, Hussein F., et al.
Publicado: (2018)

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells
por: Payne, Kyle K., et al.
Publicado: (2016)

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
por: Ascierto, Maria Libera, et al.
Publicado: (2013)

Gr1(−/low)CD11b(−/low)MHCII(+) myeloid cells boost T cell anti‐tumor efficacy
por: Payne, Kyle K., et al.
Publicado: (2018)

Tumor Escape and Progression under Immune Pressure
por: Manjili, Masoud H., et al.
Publicado: (2012)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems
por: Manjili, Masoud H., et al.
Publicado: (2012)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets
por: Aqbi, Hussein F., et al.
Publicado: (2020)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients
por: Dehghani, Mehdi, et al.
Publicado: (2020)

Anti-Neoplastic Cytotoxicity of Gemcitabine-(C(4)-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3)
por: Coyne, CP, et al.
Publicado: (2013)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

The Addition of Recombinant Vaccinia HER2/neu to Oncolytic Vaccinia-GMCSF Given into the Tumor Microenvironment Overcomes MDSC-Mediated Immune Escape and Systemic Anergy
por: de Vries, Christiaan R., et al.
Publicado: (2015)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

An immunologic portrait of cancer
por: Ascierto, Maria Libera, et al.
Publicado: (2011)

C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer
por: Schlotter, Claus M, et al.
Publicado: (2003)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
por: Li, Qingguo, et al.
Publicado: (2011)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk
por: Payne, Kyle K., et al.
Publicado: (2012)

HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma
por: Gowda, Madhu, et al.
Publicado: (2013)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_14bngas37tip71k6l6tsdkkpfv